These findings informed the development of an epigenome therapeutic approach for treating AD based on a modification of the CRISPR/Cas9 technology and delivered by an all‐in‐one viral vector platform that specifically recognizes the APOE ε4 allele and represses and fine‐tunes APOE ε4 expression. The gene discussed is APOE; the disease is Alzheimer disease.